

References

I-170

1. van Rhee F, Casper C, Voorhees PM, et al. A phase 2, open-label, multicenter study of the longterm safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease. *Oncotarget*. 2015; 30408-30419.
2. Garcia-Manero G, Gartenberg G, Steensma DP, et al. A phase 2, randomized, double-blind, multicenter study comparing siltuximab plus best supportive care (BSC) with placebo plus BSC in anemic patients with International Prognostic Scoring System low- or intermediate-1–risk myelodysplastic syndrome. *Am. J. Hematol*. 2014; E156–E162.
3. NCCN Drugs & Biologics Compendium™. Siltuximab. 2020. National Comprehensive Cancer Network (NCCN)
4. Zhao S, Wan Y, Huang Z, et al. Imaging and clinical features of Castleman Disease. *Cancer Imaging*. 2019; 19(1):53.
5. Sitenga J, Aird G, Ahmed A, Silberstein PT. Impact of siltuximab on patient-related outcomes in multicentric Castleman’s disease. *Patient Relat Outcome Meas*. 2018; 9:35.
6. Siltuximab (Sylvant), for injection [packet insert] EUSA Pharma (UK), Ltd. Hemel Hempstead, Hertfordshire, U.K. Revised 12/2019.
7. Clinical Pharmacology™ Compendium. 2020. Tampa FL: Gold Standard, Inc. Siltuximab.
8. Micromedex DrugDex Compendium®. 2020. Siltuximab.
9. Van Rhee F, Casper C, Voorhees P, et al. Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trials. *Lancet Haematol*. 2020;7(3):e209-e217.
10. Morra D, Pierson S, Shilling D, et al. Predictors of response to anti-IL6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease: secondary analyses of phase II clinical trial data. *Br J Haematol*. 2019;184(2):232-241.